Related Experiment Video
Updated: Aug 6, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
Published on: July 17, 2019
RAS degraders: The new frontier for RAS-driven cancers.
Taylor E Escher1, Karla J F Satchell1
1Department of Microbiology-Immunology, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA; Robert H. Lurie Comprehensive Cancer Research Center, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.
Researchers are developing novel RAS degraders, including PROTACs and direct proteolysis degraders, to target RAS-driven cancers. These advanced therapies offer new opportunities for effective cancer treatment and understanding cell biology.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- RAS proteins are crucial in cancer development, historically considered
- Purpose_of_the_Study
- Main_Methods
- Main_Results
- Conclusions
Purpose of the Study:
- To review recent advancements in developing RAS degraders for cancer therapy.
- To explore novel strategies targeting RAS-driven cancers.
- To highlight the potential of new therapeutics and delivery methods.
Main Methods:
- Review of recent scientific literature on RAS degraders.
- Analysis of proteolysis-targeting strategies like PROTACs and direct degraders.
- Examination of novel delivery systems for enhanced therapeutic efficacy.
Main Results:
- Development of advanced RAS degraders, including PROTACs and direct proteolysis targeting agents.
- Identification of RAS/RAP1-specific endopeptidase as a direct RAS protease degrader.
- Exploration of novel delivery strategies to improve therapeutic outcomes.
Conclusions:
- RAS degraders represent a promising frontier in cancer therapy for RAS-driven malignancies.
- Targeting RAS proteins with novel degraders offers new therapeutic avenues.
- Further research into delivery strategies will enhance the efficacy of these emerging treatments.
More Related Videos
Related Concept Videos
The Ras Gene
Ras is a...
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Abnormal Proliferation
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

